DUSP4 is associated with increased resistance against anti-HER2 therapy in breast cancer.

Autor:	Menyhart O; Semmelweis University 2nd Department of Pediatrics, Budapest, Hungary., Budczies J; Institute of Pathology, Charité University Hospital, Berlin, Germany., Munkácsy G; Semmelweis University 2nd Department of Pediatrics, Budapest, Hungary., Esteva FJ; Clinical Cancer Center, NYU Langone Medical Center, New York, NY, USA., Szabó A; Semmelweis University 2nd Department of Pediatrics, Budapest, Hungary., Miquel TP; New Terapeutics Targets Laboratory (TargetsLab), Department of Medical Sciences, University of Girona, Girona, Spain., Győrffy B; Semmelweis University 2nd Department of Pediatrics, Budapest, Hungary.; MTA TTK Lendület Cancer Biomarker Research Group, Institute of Enzymology, Budapest, Hungary.
Jazyk:	angličtina
Zdroj:	Oncotarget [Oncotarget] 2017 Aug 24; Vol. 8 (44), pp. 77207-77218. Date of Electronic Publication: 2017 Aug 24 (Print Publication: 2017).
DOI:	10.18632/oncotarget.20430
Abstrakt:	The majority of patients develop resistance against suppression of HER2-signaling mediated by trastuzumab in HER2 positive breast cancer (BC). HER2 overexpression activates multiple signaling pathways, including the mitogen-activated protein kinase (MAPK) cascade. MAPK phosphatases (MKPs) are essential regulators of MAPKs and participate in many facets of cellular regulation, including proliferation and apoptosis. We aimed to identify whether differential MKPs are associated with resistance to targeted therapy in patients previously treated with trastuzumab. Using gene chip data of 88 HER2-positive, trastuzumab treated BC patients, candidate MKPs were identified by Receiver Operator Characteristics analysis performed in R. Genes were ranked using their achieved area under the curve (AUC) values and were further restricted to markers significantly associated with worse survival. Functional significance of the two strongest predictive markers was evaluated in vitro by gene silencing in HER2 overexpressing, trastuzumab resistant BC cell lines SKTR and JIMT-1. The strongest predictive MKPs were DUSP4/MKP-2 (AUC=0.75, p =0.0096) and DUSP6/MKP-3 (AUC=0.77, p =5.29E-05). Higher expression for these correlated to worse survival (DUSP4: HR=2.05, p =0.009 and DUSP6: HR=2, p =0.0015). Silencing of DUSP4 had significant sensitization effects - viability of DUSP4 siRNA transfected, trastuzumab treated cells decreased significantly compared to scramble-siRNA transfected controls (SKTR: p =0.016; JIMT-1: p =0.016). In contrast, simultaneous treatment with DUSP6 siRNA and trastuzumab did not alter cell proliferation. Our findings suggest that DUSP4 may represent a new potential target to overcome trastuzumab resistance. Competing Interests: CONFLICTS OF INTEREST The authors declare that they have no conflicts of interest.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu